Skip to main content

Updates on Blood Cholesterol: Applying New Guidelines to Clinical Practice


A Series of CME/CE-certified Live Webinars 

TO REGISTER:

Step 1: Click here to create an account, or login if you already have an account.
Step 2: Click on the lipids webinar course to return to this page or if you are already logged in, proceed to Step 3.
Step 3: Click here to complete your registration.

DATES AND TIMES
Wednesday, September 18, 2019
12:00 Noon - 1:00 PM EST (11:00 AM - 12:00 Noon CST / 9:00 - 10:00 AM PST)
Program Faculty: Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

Tuesday, November 5, 2019
4:00 - 5:00 PM EST (3:00 - 4:00 PM CST / 1:00 - 2:00 PM PST)
Program Faculty: James A. Underberg, MD, MS, FNLA

AGENDA
Welcome and Introductions
Assessing ASCVD Risk – Role of LDL-C
Managing LDL-C to Lower ASCVD Risk
Q&A Session and Activity Roundup

PROGRAM DESCRIPTION
Cardiovascular disease is the leading cause of death in the US. While tools have been developed to identify patients at increased risk for atherosclerotic cardiovascular disease (ASCVD), these instruments are not always used in clinical practice. To improve the identification of at-risk patients, in late 2018 the American Heart Association (AHA) and American College of Cardiology (ACC) jointly published guidelines for the use of risk-assessment tools.

In November 2018, the AHA, ACC, and other partnering associations also released a “Guideline on the Management of Blood Cholesterol” to provide updated clinical recommendations for the management of elevated low-density lipoprotein cholesterol (LDL-C), a major contributor to ASCVD.This document provided strategies for primary and secondary prevention of ASCVD, along with approaches for modifying therapy in patients who are not achieving their LDL-C goals.

This activity, Updates on Blood Cholesterol: Applying New Guidelines to Clinical Practice, will review these recent evidence-based recommendations and updates, as well as providing information about non-statin agents recommended for use when patients are not at LDL-C goal.

STEERING COMMITTEE

 Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
 Professor of Medicine, Cardiology
 Director, Seinsheimer Cardiovascular Health Program
 Co-Director, Women's Heart Care
 Medical University of South Carolina
 Charleston, SC


Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
is Professor of Medicine and Cardiology at The Medical University of South Carolina, where she serves as Medical Director of the Seinsheimer Cardiovascular Health Program and Co-Director of Women’s Heart Care. Dr. Morris is a fellow of the American College of Cardiology, the American Heart Association, the American Society of Preventive Cardiology, and the National Lipid Association. She is on the Executive Committees of the National Lipid Association and the American Board of Clinical Lipidology. She has been selected as Vice-Chair (2019-2020) and Chair (2021-2022) of the American College of Cardiology Annual Scientific Sessions. She also serves as Associate Editor of the Journal of the American College of Cardiology.

  James A. Underberg, MD, MS, FNLA
  Past-President, National Lipid Association
  President, American Board of Clinical Lipidology
  Clinical Assistant Professor of Medicine
  NYU School of Medicine
  NYU Center for Prevention of Cardiovascular Disease
  Director, Bellevue Hospital Lipid Clinic
  New York, NY

James A. Underberg, MD, MS, FNLA is a clinical lipidologist and a Clinical Assistant rofessor of Medicine at the NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic.

Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and a Fellow and Past-President of the National Lipid Association (NLA). He is a board member for the NLA and the Foundation of the NLA, as well as the President of the American Board of Clinical Lipidology.

Dr. Underberg’s clinical interests focus on the management of patients with lipids and lipoprotein disorders, the management of hypertension, and the prevention of cardiovascular disease. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of clinical lipidology. He sees patients both at Bellevue Hospital and in a university-based private-practice setting.

Kim K. Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE
Clinical Professor
University of Houston College of Pharmacy
Houston, TX



Kim K. Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE
 is a Clinical Professor at the University of Houston College of Pharmacy. She is also a clinical pharmacist in Kelsey-Seybold Clinic’s Cardiology Clinic in Houston, TX, where she is responsible for the Secondary Prevention Lipid Clinic. Her teaching and research interests are in cardiovascular risk reduction and quality improvement initiatives.

Dr. Birtcher received her bachelor's in pharmacy and master's in pharmacy administration from the University of Texas at Austin. She received her Doctor of Pharmacy from the University of Florida. Dr. Birtcher is a certified diabetes educator and board-certified pharmacotherapy specialist with additional qualifications in cardiology. She is an Associate of the American College of Cardiology and a Fellow of the National Lipid Association. Dr. Birtcher is an active member of the American College of Cardiology, having served on many committees, and a member of the Southwest Lipid Association.

Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN
Professor of Nursing and Medicine 
Nurse Practitioner, Rush Heart Center for Women
LaGrange, IL




Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN 
is a Professor in the Department of Adult Health and Gerontological Nursing, Rush University College of Nursing, as well as a Professor in the Department of Internal Medicine, Rush University Medical Center. She is a nurse practitioner in the Rush Heart Center for Women, where she focuses on prevention. Dr. Braun’s clinical and research interests include cardiovascular risk reduction, exercise, cardiac rehabilitation, hyperlipidemia, and hypertension management. Dr. Braun holds a PhD in Nursing Science from the University of Illinois at Chicago. She is board-certified as an Adult Nurse Practitioner from the ANCC. She is also a Diplomate of the Accreditation Council of Clinical Lipidology.

Dr. Braun served as co-investigator for three research grants funded by the National Institutes of Health, most recently the study, "Reducing Health Disparity in African American Women: Adherence to Physical Activity." She is a co-author of five AHA/ACC Scientific Statements, the AHA/ACC statement on Performance Measures for the Primary Prevention of Cardiovascular Disease, and three AHA clinical practice guidelines, including the 2018 Multi-Society Guideline on the Management of Blood Cholesterol. She chaired the AHA policy statement on palliative care in cardiovascular disease and stroke. She has served as consultant to the CDC's Division for Heart Disease and Stroke Prevention for several projects. Dr. Braun is an editorial board member for the Journal of Clinical Lipidology; she serves as reviewer for numerous other journals.

Dr. Braun is an elected Fellow of the American Academy of Nursing, the American Heart Association, the Institute of Medicine of Chicago, the National Lipid Association, the American Association of Nurse Practitioners, and the Preventive Cardiovascular Nurses Association. 

TARGET AUDIENCE

This activity is intended for primary care clinicians, cardiologists, and other clinicians who manage patients who are at risk for or have ASCVD.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Use guideline-recommended tools to evaluate the need for blood cholesterol management for primary ASCVD prevention in patients without clinical ASCVD
  • Implement the 2018 cholesterol guidelines when developing individualized primary prevention strategies for patients with and without severe hypercholesterolemia
  • Develop management plans for the secondary prevention of ASCVD using recommendations from the 2018 blood cholesterol guidelines
  • Intensify LDL-C management using adjunctive non-statin therapy when secondary prevention with statins alone does not achieve 2018 blood cholesterol guideline goals
ACCREDITATION
In support of improving patient care, this activity has been planned and implemented by the National Lipid Association and Rockpointe Corporation. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For information about the accreditation of this program, please email cme@lipid.org.

PHYSICIAN CREDIT DESIGNATION 
The National Lipid Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

PHYSICIAN ASSISTANTS CREDIT DESIGNATION

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

PHARMACISTS CREDIT DESIGNATION

Universal Activity Number: JA0007192-9999-19-041-L01-P (Knowledge).


This activity has been approved for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

NURSES CREDIT DESIGNATION
The maximum number of hours awarded for this CE activity is 1.0 contact hours. 

DISCLOSURE STATEMENT

The National Lipid Association (NLA) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by NLA are required to disclose any relevant financial relationships with any commercial interest to NLA as well as to learners. All conflicts of interest are identified and resolved by NLA in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of 
this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

FACULTY DISCLOSURES 

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA: Consultant: Akcea; Local PI, Clear Outcomes Study: Esperion

James A. Underberg, MD, MS, FNLA:
Speaker: Amgen, Alexion, Amarin, Akcea, Sanofi, Regenron; Advisory Board: Amgen, Alexion, Sanofi, Regeneron, Akcea, Amarin; Consultant: Amgen, Ambry; Contracted Research: Aegerion, Pfizer 

 Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAANP, FNLA, FAAN: Nothing to disclose

Kim K. Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE: Nothing to disclose

NON-FACULTY CONTENT CONTRIBUTORS

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Blair St. Amand; NLA Staff and Reviewer Scott W. Shurmur, MD, FNLA: Nothing to disclose

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of a
pproved uses. 

SYSTEM CHECK

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CE CREDIT

There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 80% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
ate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times. 

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit. s Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Jointly provided by the National Lipid Association and Rockpointe
   

This activity is supported by educational funding provided by Amgen.